英夫利昔单抗治疗后多发性角化棘皮瘤和鳞状细胞癌的急性发展
Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab.
作者信息
Esser Adam C, Abril Andy, Fayne Scott, Doyle John A
机构信息
Department of Dermatology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
出版信息
J Am Acad Dermatol. 2004 May;50(5 Suppl):S75-7. doi: 10.1016/j.jaad.2003.11.044.
Infliximab, a chimeric mouse-human monoclonal antibody, blocks the action of tumor necrosis factor-alpha and is a highly effective treatment for several inflammatory disorders, including inflammatory bowel disease and rheumatoid arthritis. Although safety data are encouraging, immunosuppressive sequelae may result. We report the acute development of multiple squamous cell carcinomas and keratoacanthomas in a patient receiving infliximab for rheumatoid arthritis.
英夫利昔单抗是一种嵌合型鼠-人单克隆抗体，可阻断肿瘤坏死因子-α的作用，是治疗多种炎症性疾病（包括炎症性肠病和类风湿性关节炎）的高效药物。尽管安全性数据令人鼓舞，但可能会产生免疫抑制后遗症。我们报告了一名接受英夫利昔单抗治疗类风湿性关节炎的患者急性发生多发性鳞状细胞癌和角化棘皮瘤的情况。
Zotero 插件